---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-014239"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2024-03-20T23:59:59+00:00"
generated_at: "2026-06-04T11:23:05.277529+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Femasys: 24% pregnancy rate with FemaSeed in severe male factor infertility trial, more than triple IUI rate

## Summary
- Pivotal trial: 24% of women became pregnant after FemaSeed in severe male factor (TMSC 1M-20M), vs 6.7% per cycle for IUI in literature.
- Majority of successful pregnancies required only one FemaSeed procedure.
- No new safety concerns; adverse events mild and consistent with known IUI events.
- FDA clearance obtained September 2023; commercial launch planned first half of 2024.
- Capital infusion at end of 2023 provides funding into second half of 2025.

## SEC filing metadata
- accession: 0001140361-24-014239
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2024-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036124014239/0001140361-24-014239-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036124014239/ef20024684_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-014239
- JSON: https://secwatch.observer/filing/0001140361-24-014239.json
- Plain text: https://secwatch.observer/filing/0001140361-24-014239.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.